Big data and cancer

Laura Pedulli | | Health Exec | Digital Transformation

If big data is so useful in medicine, why isn’t it more widespread? The “stubborn culture of medicine” and slow technological adoption are some of the culprits, according to U.S. News & World Report.

But while progress is slow, patient demands and pressures from the Affordable Care Act may mean that the tipping point has come.

Read more below:

Can Big Data Cure Cancer?

Laura Pedulli

Related Content

5 ways to let AI raise patient satisfaction, elevate provider performance
When life sciences met artificial intelligence
AdvaMed itemizes AI imperatives for ‘the entire healthcare ecosystem’
6 things high-achieving orgs do to wring real value from AI
A modest proposal to rally AI regulators around a simple game plan
4 points crucial to the nimble regulation of GenAI

Around the web

Cardiovascular Business
Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”